What factors influence your decision regarding whether to administer a dose-dense chemotherapy regimen in the adjuvant setting to patients with hormone-receptor postive disease?  

Data presented at the 2017 SABCS (abstract GS1-01) of the EBCTCG meta-analysis stating a benefit of dose-dense chemotherapy applies to ER positive and negative patients seems to conflict with prior data reflected in a 2015 meta-analysis of >17,000 patients (Petrelli et al. Breat Cancer Reserach & Treatment 2015) which found the OS benefit was not seen in ER positive patients (HR 0.93, 95% CI 0.82-1.05, p=0.25).



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution